Navigation Links
Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Date:6/6/2008

women's empowerment. Yet, too often, an obstacle prevents millions of women from living healthy, productive lives: cancer. Cervical cancer kills more than a quarter million women each year, and nearly all of these deaths are preventable. New vaccines and a highly accurate test for HPV have the power to eliminate this devastating disease. But we need help in assuring access to these medical advances for all women, and we welcome QIAGEN's commitment and leadership."

In addition to its digene HPV Test, which QIAGEN distributes widely in the United States, Europe and elsewhere, the company is partnering with the non-profit organization PATH to develop a specially designed version of the screening test for low-resource countries. This new test is sensitive enough to identify the largest number of women at risk - a critical characteristic when a woman may be able to get to a medical clinic just once or twice in her lifetime. Yet at the same time, the new HPV test can be run without electricity or running water, and can be administered by workers with minimal training.

"Public-private partnerships are essential to advancing the health agenda for women, and QIAGEN is committed to leading the way," Mr. Schatz told the audience at a panel discussion on corporate social responsibility at the summit. "We look forward to working in tandem with the many partners we have found at this summit and elsewhere."

About HPV and cervical cancer (http://www.theHPVtest.com)

Worldwide, cervical cancer affects nearly 500,000 women annually and, after breast cancer, is the second most common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causi
'/>"/>

SOURCE QIAGEN NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
4. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
5. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
8. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
9. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
10. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
11. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Pharma,s eFlow,electronic nebulizer was included in Gilead,s (Nasdaq: ... to the U.S. Food and Drug Administration,(FDA) for ... mg,three times daily). Aztreonam lysine for inhalation, delivered ... people with cystic fibrosis,(CF) who have pulmonary Pseudomonas ...
... large, randomized Phase III trials of VELCADE in front-line, ... ... Mass., Nov. 26 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today ... studies are scheduled to be,featured at the 49th ASH Annual Meeting ...
Cached Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
(Date:9/30/2014)... no stranger to the children of Tanzania. What is ... clinical services, including reliable diagnosis and evidence-based treatments. There ... use in Swahili, a major language of the region. ... University and the University of Georgia (UGA) describe a ... sites in the country and found to be effective ...
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... September 30, 2014 Glycodrive , ... Nutraceuticals designed to help maximize lean, strong muscle growth ... body’s absorption of glucose has caught the attention of ... main purpose behind Glycodrive is to help the body ... reports Michaels. “Carbs are essential in the muscle-building process, ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... program delivered by over 500 peer volunteers significantly reduces ... researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress ... Program (CHAP), family physicians in 20 mid-sized Ontario communities ... assessment sessions held at local pharmacies over a 10 ...
... British Columbia (June 7, 2010) Researchers from the ... University of British Columbia today released a comprehensive study ... HIV treatment would create significant benefits for individuals infected ... peer-reviewed mathematical modeling study, published in the research journal ...
... Susan G. Komen for the Cure has appointed V. ... Council. Jordan, a member of the National Academy of ... department of oncology at the Lombardi Comprehensive Cancer Center at ... appointment to the Komen Scientific Advisory Council is reserved for ...
... WASHINGTON, June 7, 2010 Those social drinkers who order ... default "well" liquor. Are they just vodka snobs, who pay ... possibly taste much different than its $6 counterpart? Or is ... claim to taste in America,s favorite hard liquor? ...
... survivors diagnosed later with non-melanoma skin cancer may be ... 15 years, according to research led by St. Jude ... survivors in this Childhood Cancer Survivor Study (CCSS) who ... developed another more aggressive cancer within 15 years, said ...
... in German . Early detection is the ... lump turns out to be a malignant tumor. To find ... biopsy and examine the removed tissue under the microscope. This ... also highly time consuming. Research scientists at the Fraunhofer Institute ...
Cached Medicine News:Health News:A good CHAP reduces rates of heart disease and stroke in communities. 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 2Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 4Health News:Brand preference may be in the drink, not in the head 2Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Detecting tumors faster 2
... single use loading unit (SULU), the EEA™ ... staples., ,Immediately after staple formation, a ... excess tissue, thus creating a circular anastomosis. ... handles firmly as far as they will ...
... The Scantibodies Calcitonin Immunoassay is a ... of calcitonin. Two different goat polyclonal antibodies ... affinity chromatography to be specific for well-defined ... the quantitative determination of Calcitonin in human ...
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Calcitonin RIA Kit...
Medicine Products: